Initially identified as an RNA modification in the anticodon loop of tRNAs from animal, plant and eubacterial origin, the deamination of adenosine-to-inosine by RNA editing has become increasingly recognized as an important RNA processing event to generate diversity in both the transcriptome and proteome and is essential for modulating the activity of numerous proteins critical for nervous system function. Here, we focus on the editing of transcripts encoding the 2C-subtype of serotonin receptor (5HT 2C ) to generate multiple receptor isoforms that differ in G-protein coupling efficacy and constitutive activity. 5HT 2C receptors have been implicated in the regulation of anxiety, components of the stress response, and are thought to play a role in compulsive behavioral disorders, depression and drug addiction. A number of studies have been conducted to assess whether 5HT 2C editing is altered in individuals suffering from psychiatric disorders, yet the results from these studies have been inconsistent, and thus inconclusive. This review provides a discussion of the challenges involved with characterizing 5HT 2C editing patterns in human postmortem tissue samples and how differences in quantitative methodology have contributed to the observed inconsistencies between multiple laboratories. Additionally, we discuss new high-throughput sequencing tools, which provide an opportunity to overcome previous methodological challenges, and permit reliable systematic analyses of RNA editing in control and pathologic disease states.
Introduction
A major goal of current neurobiology research is to define and characterize the cellular and molecular pathophysiology underlying nervous system dysfunction including neurodegenerative disorders and psychiatric illness. Over the past two decades, a fundamental component of this effort has involved human postmortem brain studies where gene expression profiles of matched tissue samples from healthy individuals and patients diagnosed with specific nervous system disorders have been compared (Horvath et al., 2011; Iwamoto and Kato, 2006; Mehta et al., 2010; Sequeira and Turecki, 2006) . While this traditional approach can be confounded by a number of variables such as postmortem interval, medication history, secondary effects of illness, cause of death and the small number of brain samples available for analysis (Bahn et al., 2001; Mirnics and Pevsner, 2004; Mirnics et al., 2004) , technical artifacts of gene expression analysis may also contribute to inconsistencies between published datasets among multiple laboratories. The majority of transcriptomewide gene expression studies have taken advantage of microarray strategies to simultaneously compare the relative expression of thousands of RNAs across sets of tissue samples. A limitation to this probebased approach results from the inherent requirement to design Neurobiology of Disease 45 (2012) 8-13 
